Global EditionASIA 中文双语Fran?ais
China
Home / China / Health

More talks sought to drop cancer drug costs

By Wang Xiaoyu | China Daily | Updated: 2019-02-20 07:06 菲律宾申博太阳城官网
A pharmacist works at the dispensary of a cancer hospital in Hainan province in January. [Photo/VCG]

The country's top medical insurance regulator plans more talks with pharmaceutical companies to lower the prices of cancer drugs, following negotiations last year that are thought to have benefited a large number of patients.

In October, 17 cancer-related medications were introduced to China's basic medical insurance program, meaning they would be eligible for reimbursement, according to the National Healthcare Security Administration.

As of year's end, about 45,000 reimbursed payments for these drugs totaling 256 million yuan ($38 million) had been processed, said Xiong Xianjun, head of the administration's department that compiles the insurance program list. He spoke on Tuesday.

Xiong said larger reimbursements were made possible by negotiations with pharmaceutical companies in September, leading to price reductions.

Average reductions were 56.7 percent, Xiong said, adding that imported drugs can be purchased at a price about 36 percent lower than in nearby countries and regions.

Medical institutions and drugstores across the country made purchases at the newly capped prices of 184 million units of medication last year. They cost about 562 million yuan, a cost that, given the particular drugs purchased, would have been almost triple the amount if bought at their original prices.

"This year, we're eyeing more negotiations with drug manufacturers to lower prices of more cancer drugs, especially the lifesaving types and those in critical need," he said at a news conference organized by the State Council Information Office.

In recent years, China has raced to help cancer patients by pushing down drug prices, accelerating inspection and approval procedures for new drugs developed overseas, and improving medical services needed by the patients.

Price negotiations, first tested by China in 2015, are expected to play a larger role in making cancer drugs more affordable and reducing patients' financial burden, he said.

The administration said earlier this month that 34 medications that treat major cancers, including the 17 newly added drugs, have been included in the basic medical insurance program.

Li Bin, vice-minister of the National Health Commission, said 802 cancer or other specialist hospitals had purchased these drugs and 259 among them bought at least four by year's end.

The commission has urged all medical institutions to stock an adequate supply of such cancer drugs, and medical institutions should refrain from citing excuses to keep from doing so like the need to contain costs, Li said.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
网站地图 幸运大转盘 保险百家乐 777老虎机游戏登入 申博登入网址
菲律宾申博怎么充值登入 申博游戏开户 申博亚洲官方网站 菲律宾太阳城娱乐登入
澳门星际赌场 太阳城亚洲 菲律宾太城申博 申博游戏手机下载
申博代理 太阳城亚洲注册 澳门新葡京赌场 申博娱乐官网
盛618官网 申博娱乐开户 网上百家乐 申博游戏登入不了